Market capitalization | $6.75b |
Enterprise Value | $9.54b |
P/E (TTM) P/E ratio | 13.86 |
EV/FCF (TTM) EV/FCF | 6.41 |
EV/Sales (TTM) EV/Sales | 2.35 |
P/S ratio (TTM) P/S ratio | 1.66 |
P/B ratio (TTM) P/B ratio | 1.62 |
Revenue growth (TTM) Revenue growth | 5.76% |
Revenue (TTM) Revenue | $4.06b |
As a Free StocksGuide user, you can view scores for all 6,808 stocks worldwide.
20 Analysts have issued a Jazz Pharmaceuticals Plc forecast:
20 Analysts have issued a Jazz Pharmaceuticals Plc forecast:
Mar '25 |
+/-
%
|
||
Revenue | 4,065 4,065 |
6%
6%
|
|
Gross Profit | 3,610 3,610 |
5%
5%
|
|
EBITDA | 1,221 1,221 |
3%
3%
|
EBIT (Operating Income) EBIT | 595 595 |
4%
4%
|
Net Profit | 482 482 |
46%
46%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Head office | Ireland |
CEO | Bruce Cozadd |
Employees | 2,800 |
Founded | 2005 |
Website | www.jazzpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.